The market for weight loss drugs is exploding and patients may have several new options in coming years—here's a look, in chartsWSJ • 03/26/26
LLY or ABBV: Which Drugmaker is Likely to Offer Better Upside in 2026?Zacks Investment Research • 03/25/26
U.S. executives, from Apple to Eli Lilly, revamp their push into the world's second-largest economy at the China Development ForumCNBC • 03/23/26
LLY's Next-Gen Obesity Drug Meets Goal in First Phase III Study for T2DZacks Investment Research • 03/20/26
Lilly GLP-1 drug rivals Novo's pipeline treatment on gut side effects but throws up skin concernProactive Investors • 03/20/26
Eli Lilly's next-generation obesity drug delivers strong results in late-stage trialProactive Investors • 03/19/26
Eli Lilly's Experimental Drug Retatrutide Delivers Strong Weight Loss In Late-Stage TrialInvestors Business Daily • 03/19/26
Eli Lilly's next-generation obesity drug retatrutide clears first late-stage diabetes trialCNBC • 03/19/26
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetesPRNewsWire • 03/19/26
Healthy Returns: Stopping GLP-1s raises risk of heart attack, stroke and death, study saysCNBC • 03/18/26
Roche Vs. Eli Lilly: Nvidia Deals, Obesity Battles Stoke Rivalry (I'd Buy Both)Seeking Alpha • 03/18/26